News

Filter

Current filters:

None

8501 to 8510 of 95986 results

Amgen shares jump as firm unveils plans for a $5 billion stock purchase

08-11-2011

USA-based Amgen (Nasdaq: AMGN), the world’s largest independent biotech firm, saw its shares leap…

AmgenBiotechnologyFinancial

Will the USA’s Hatch-Waxman lock be sprung in 2012? asks HP&M lawyer

08-11-2011

In the USA, there have been rumors for several weeks that, once the ball gets rolling in Congress with…

GenericsLegalNorth AmericaPharmaceuticalPoliticsRegulation

Recordati’s Normosang now approved in Russia; posts strong financials

08-11-2011

Italian drugmaker Recordati (REC: MI) and wholly-owned subsidiary Orphan Europe announced that Normosang,…

EuropeFinancialNormosangPharmaceuticalRare diseasesRecordatiRegulation

Another call for reform of Canada’s pharma intellectual property laws

08-11-2011

Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation…

North AmericaPatentsPharmaceutical

South Korean govt to slash drug prices 14%

08-11-2011

South Korea’s Ministry of Health and Welfare has issued an advance notice of the legislation of…

Asia-PacificPharmaceuticalPoliticsPricingResearch

FDA accepts VIVUS NDA filing for Qnexa with PDUFA set for April 2012

08-11-2011

There was good news for US drugmaker VIVUS (Nasdaq: VVUS) in its long-running battle to get its weight-loss…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Added indication for Bristol-Myers’ Erbitux approved by FDA

08-11-2011

The US Food and Drug Administration yesterday approved US drug major Bristol-Meyers Squibb’s (NYSE:…

Bristol-Myers SquibbErbituxNorth AmericaOncologyPharmaceuticalRegulation

Ph III study shows Novartis’ canakinumab substantially reduces steroid use in children with SJIA

08-11-2011

Swiss drug major Novartis (NOVN: VX) says new pivotal Phase III data show that 45% of children with active…

Anti-Arthritics/RheumaticsCanakinumab InjectionIlarisNovartisResearch

8501 to 8510 of 95986 results

Back to top